AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 10, 2018
August 30 2018 - 4:05PM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced that it will report financial
results for the fiscal quarter and year ended June 30, 2018 after
the market closes on Monday, September 10, 2018. AGTC management
will host a conference call beginning at 4:30 PM Eastern Time that
day to review results and provide a corporate update.
To access the call, dial 877-407-6184 (US) or
201-389-0877 (outside of the US). The passcode is 13682770. A live
webcast will be available in the Events and Presentations section
of the Investor Relations page at
http://ir.agtc.com/events-and-presentations. Please log in
approximately 10 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and
Presentations section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company
that uses a proprietary gene therapy platform to develop
transformational genetic therapies for patients suffering from rare
and debilitating diseases. Its initial focus is in the field of
ophthalmology, where it has active clinical trials in X-linked
retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and
achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its
clinical trials, AGTC has preclinical programs in optogenetics,
adrenoleukodystrophy (ALD), which is a disease of the central
nervous system (CNS), and otology. The clinical-stage XLRS and XLRP
programs, the discovery program in ALD and two additional
ophthalmology programs are being developed in collaboration with
Biogen, and the optogenetics program is being developed in
collaboration with Bionic Sight. In addition to its product
pipeline, AGTC has a significant intellectual property portfolio
and extensive expertise in the design of gene therapy products
including capsids, promoters and expression cassettes, as well as
expertise in the formulation, manufacture and physical delivery of
gene therapy products.
IR/PR CONTACTS: David Carey (IR)
or Tom Vickery (PR) Lazar Partners Ltd. T: (212) 867-1768
or (646) 871-8482
dcarey@lazarpartners.com or tvickery@lazarpartners.com
Corporate Contacts: Bill Sullivan Chief
Financial Officer Applied Genetic Technologies Corporation T: (617)
843-5728 bsullivan@agtc.com
Stephen Potter Chief Business Officer Applied Genetic
Technologies Corporation T: (617) 413-2754
spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2024 to May 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From May 2023 to May 2024